Week in Review: CITIC Offers $3.6 Billion To Acquire China Biologic
June 23, 2018 at 18:27 PM EDT
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's top five plasma-based biopharmas (. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding.